868-869 / 2437
Low grade astrocytoma
•
Chemotherapy can be a therapeutic option to defer, or an
alternative to RT at progression, but, deferring RT must be
balanced with the lower control of seizures and shorter PFS
1,2
•
Long term results of athe RTOG 9802 trial showed a survival
advantage of 5.5 years by addition of chemotherapy to RT in
patients with adverse prognostic factors
2
•
The same experience indicates that treatment of LGG patients,
immediately after surgery or at progression, should be tailored
according to specific prognostic factors
1-5
•
Patients’ subgroups should be treated and trials should be designed
according to specific biomarkers, being IDH mutation and 1p/19q
codeletion the most relevant
1-5
1.
Baumert, et al. Lancet Oncol 2016
2.
Buckner, et al., NEJM 2016
3.
Soffietti, et al. EJN 2010
4.
Gorlia, et al. Neuro-Oncol 2013
5.
Weller, et al, Lancet Oncol, 2017